Three Conventional-Drug Combination (Ifosfamide, Carboplatin, Etoposide - ICE Regimen) in Advanced Non-Small Cell Lung Cancer (NSCLC)

Fifty consecutive patients with stage IIIB-IV non-small cell lung cancer (NSCLC) received the ICE regimen at intermediate doses (ifosfamide 1 g/m 2 , carboplatin 120 mg/m 2 , etoposide 80 mg/m 2 , day 1 to 3, q.4 weeks, for a maximum of 6 cycles). Overall 2 complete response (CR) and 10 partial resp...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chemotherapy (Florence) 2001-08, Vol.13 (4), p.434-439
Main Authors: Cuomo, A.M., Cuna, F.S. Robustelli Della, Baiardi, P., Torazzo, R., Preti, P., Cuna, G. Robustelli Della
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Carboplatin - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Chemotherapy
Dose-Response Relationship, Drug
Drug toxicity and drugs side effects treatment
Etoposide - therapeutic use
Female
Humans
Ifosfamide - therapeutic use
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Male
Medical sciences
Middle Aged
Neoplasm Staging
Pharmacology. Drug treatments
Survival Rate
Toxicity: blood
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fifty consecutive patients with stage IIIB-IV non-small cell lung cancer (NSCLC) received the ICE regimen at intermediate doses (ifosfamide 1 g/m 2 , carboplatin 120 mg/m 2 , etoposide 80 mg/m 2 , day 1 to 3, q.4 weeks, for a maximum of 6 cycles). Overall 2 complete response (CR) and 10 partial response (PR) (overall response, OR: 24%, 95% C.I. 14-37%) were observed. An additional 7 patients had stable disease (SD) lasting more than 6 months, therefore a clinical benefit (CR+PR+SD >6 mos) was achieved in 19 patients (38%). Median time-to-progression (TTP) was 7 months and median overall survival (OS) was 11 months; 1- and 2-year survival rates were 36% and 10%. The ICE regimen was well tolerated and devoid of any cardiac, hepatic or neurologic toxicity. Moderate nausea and vomiting were easily manageable, grade 2 alopecia was universal, while hematological toxicity was mild (grade 2 leuko-and thrombocytopenia). Due to its efficacy and safety profile, this 3-drug regimen can be considered for routine community use.
ISSN:1120-009X
1973-9478
DOI:10.1179/joc.2001.13.4.434